Olema Pharmaceuticals Q4 EPS $(0.49) Misses $(0.48) Estimate
Portfolio Pulse from Happy Mohamed
Olema Pharmaceuticals (NASDAQ:OLMA) reported Q4 earnings with losses of $(0.49) per share, missing the consensus estimate of $(0.48) by 2.08%. However, this represents a 24.62% improvement over the previous year's losses of $(0.65) per share.
March 11, 2024 | 8:04 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Olema Pharmaceuticals reported a Q4 EPS loss of $(0.49), missing estimates by 2.08% but showing a 24.62% improvement over last year.
Missing the EPS estimate could lead to negative investor sentiment in the short term, despite the year-over-year improvement in losses. The miss, although slight, may cause concern among investors about the company's ability to meet financial expectations, potentially leading to a decrease in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100